GeneDx Holdings Corp. reported its second quarter 2025 financial results on July 29, 2025, achieving a record $102.7 million in total revenue, a 46% increase year-over-year. The company's core exome and genome business saw revenues surge by 69% year-over-year to $85.9 million, driven by a 28% rise in test volumes to 23,102 tests.
The company marked its fourth consecutive quarter of profitability on an adjusted net income basis, reporting $15.0 million for Q2 2025. Adjusted gross margin expanded to 70.6%, up from 62.2% in the prior year's quarter, reflecting improved reimbursement rates and a favorable test mix.
GeneDx significantly raised its full-year 2025 revenue guidance to between $400 million and $415 million, up from the previous range of $360 million to $375 million. The guidance for exome and genome revenue growth was also increased to 48%-52%, while adjusted gross margin guidance was raised to 68%-71%, signaling strong confidence in continued operational performance and market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.